Drug Interaction Study Evaluating the Effect of Rifampin on PK and Safety of PF 04965842.

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 13, 2018

Primary Completion Date

December 14, 2018

Study Completion Date

December 14, 2018

Conditions
Healthy
Interventions
DRUG

PF-04965842

single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.

OTHER

rifampin

In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit, Brussels

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03637790 - Drug Interaction Study Evaluating the Effect of Rifampin on PK and Safety of PF 04965842. | Biotech Hunter | Biotech Hunter